This fact sheet describes the estimated rates of recurrence of selected cancers.
This fact sheet provides patient-focused information about the FDA drug approval process and guidance on researching FDA-approved agents for patients with cancer.
This fact sheet discusses the importance of palliative care as it pertains to cancer survivorship.
This fact sheet discusses the research on supplement use and cancer incidence.
This fact sheet discusses the risk of familial exposure to radiation during cancer treatment and strategies to help limit incidental contact with potentially harmful byproducts.
Few studies have evaluated the general exposure to plastics and cancer risk, and data on cancer risk among workers in the plastic industry are inconclusive.
There are no data on whether a vegan diet is an effective means of cancer prevention among high-risk populations.
This fact sheet informs patients about what to expect prior to, during, and after a tissue biopsy.
This fact sheet about sexual health provides patients with an overview of the way in which cancer treatment can affect sexual health and management options.
This fact sheet describes patient-directed strategies for finding clinical trials.
An overview of the potential immune-related adverse events that can arise from treatment with checkpoint inhibitors.
Both the chemotherapy regimen selected and therapeutic dose intensity used in treatment factor into the calculation of neutropenia risk.
Traditional genetic testing historically included the sequential analysis of single and generally well-described genes involved in heritable cancers.
Some data suggest that psychotherapy may benefit patients with cancer, but higher-quality research is needed.
The effect of polypharmacy and noncancer mortality on patient survival and other outcomes in cancer varies by study.
Though it is clear that cancer is associated with an extreme financial burden, the extent of the burden varies widely.
There is concern that added nitrates and nitrites are associated with an increased risk of cancer, but epidemiologic data have been inconclusive thus far.
The mechanisms that drive this benefit are not well-understood, and it is believed that the benefit is not just a result of reducing risk factors such as body weight.
An overview of the research regarding the use of massage to improve cancer- or treatment-related symptoms and overall quality of life for patients with cancer.
Multiple studies have examined the possible association between cell phone usage and increased cancer risk, but study designs, potential biases, and interpretations of statistical outcomes leave conclusions uncertain.
All meta-analyses conducted to date show a significant association between indoor tanning use and an increased risk of melanoma or non-melanoma skin cancers.
Though mechanisms of anticancer effects of resveratrol have been identified, the ability to translate these findings to in-human studies is a challenge.
Several meta-analyses suggest that coffee consumption may decrease the risk of many types of cancers, but for some cancers, the data remain mixed or indicate an increased risk.
Though the mechanisms of action of acupuncture are not well-understood and continue to be an area of research, hypotheses include changes in neurohormones and immunomodulation through cytokines.
While some in vitro data suggests anticancer activity, animal and in-human studies fail to show efficacy and the risk of cyanide toxicity make amygdalin not recommended for use.
Cannabis and its synthetic cannabinoids have been studied for medicinal properties across multiple disease states.
In-human studies have evaluated the use of EOs in a supportive role, and though EOs appear to have some efficacy in this setting, larger studies are needed to confirm their effects.
Cascara use is not recommended because there are insufficient data for establishing its safety, and there have been reports of liver injury with high doses.
In vitro and in vivo data suggest that selective amino acid deprivation may have anticancer activity.
Bloodroot-containing products sold as a cure for cancer can be highly toxic and result in disfigurement.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer
- Rates of Adverse Events Similar Regardless of IMRT Boost Type